INR 431.7
(-0.22%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 1.16 Billion INR | -24.5% |
2022 | 5.72 Billion INR | 177.76% |
2021 | 2.06 Billion INR | 0.34% |
2020 | 2.05 Billion INR | 13.27% |
2019 | 1.81 Billion INR | 26.98% |
2018 | 1.42 Billion INR | 7.12% |
2017 | 1.33 Billion INR | 7.52% |
2016 | 1.23 Billion INR | 16.65% |
2015 | 1.06 Billion INR | 10.52% |
2014 | 961.34 Million INR | 7.03% |
2013 | 898.18 Million INR | 14.93% |
2012 | 781.5 Million INR | 16.89% |
2011 | 668.54 Million INR | 55.66% |
2010 | 429.5 Million INR | 10.74% |
2009 | 387.83 Million INR | 23.69% |
2008 | 313.56 Million INR | 20.22% |
2007 | 260.81 Million INR | -1.77% |
2006 | 265.51 Million INR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 1.51 Billion INR | 6.33% |
2024 Q1 | 1.04 Billion INR | -6.36% |
2023 Q3 | 1.43 Billion INR | -3.66% |
2023 FY | 4.32 Billion INR | -24.5% |
2023 Q4 | 1.11 Billion INR | -22.36% |
2023 Q1 | 1.43 Billion INR | -1.75% |
2023 Q2 | 1.48 Billion INR | 3.75% |
2022 FY | 5.72 Billion INR | 177.76% |
2022 Q3 | 1.43 Billion INR | -1.36% |
2022 Q2 | 1.44 Billion INR | 4.74% |
2022 Q4 | 1.45 Billion INR | 1.98% |
2022 Q1 | 1.38 Billion INR | 180.85% |
2021 FY | 2.06 Billion INR | 0.34% |
2021 Q1 | 1.16 Billion INR | 191.16% |
2021 Q2 | 1.22 Billion INR | 5.56% |
2021 Q3 | 1.37 Billion INR | 12.29% |
2021 Q4 | -1.71 Billion INR | -224.09% |
2020 Q2 | 1.16 Billion INR | 12.08% |
2020 Q3 | 1.13 Billion INR | -2.31% |
2020 Q4 | -1.27 Billion INR | -212.62% |
2020 Q1 | 1.03 Billion INR | 182.74% |
2020 FY | 2.05 Billion INR | 13.27% |
2019 FY | 1.81 Billion INR | 26.98% |
2019 Q4 | -1.25 Billion INR | -215.72% |
2019 Q3 | 1.08 Billion INR | 3.13% |
2019 Q2 | 1.04 Billion INR | 12.29% |
2019 Q1 | 933.9 Million INR | 192.58% |
2018 Q2 | 792.9 Million INR | 1.48% |
2018 FY | 1.42 Billion INR | 7.12% |
2018 Q4 | -1 Billion INR | -217.02% |
2018 Q3 | 862 Million INR | 8.71% |
2018 Q1 | 781.3 Million INR | 0.57% |
2017 Q1 | 704.6 Million INR | 2.26% |
2017 Q3 | 788.4 Million INR | 4.52% |
2017 Q4 | 776.9 Million INR | -1.46% |
2017 FY | 1.33 Billion INR | 7.52% |
2017 Q2 | 754.3 Million INR | 7.05% |
2016 Q2 | 669 Million INR | 8.52% |
2016 FY | 1.23 Billion INR | 16.65% |
2016 Q3 | 660.7 Million INR | -1.24% |
2016 Q4 | 689 Million INR | 4.28% |
2016 Q1 | 616.5 Million INR | 1.63% |
2015 Q2 | 563.6 Million INR | 4.84% |
2015 Q3 | 563.2 Million INR | -0.07% |
2015 FY | 1.06 Billion INR | 10.52% |
2015 Q4 | 606.6 Million INR | 7.71% |
2015 Q1 | 537.6 Million INR | 198.02% |
2014 Q3 | 507.5 Million INR | -1.67% |
2014 Q2 | 516.1 Million INR | 6.11% |
2014 Q1 | 486.4 Million INR | 195.9% |
2014 FY | 961.34 Million INR | 7.03% |
2014 Q4 | -548.45 Million INR | -208.07% |
2013 Q2 | 480.8 Million INR | 8.43% |
2013 Q3 | 481.2 Million INR | 0.08% |
2013 Q1 | 443.4 Million INR | 14.54% |
2013 FY | 898.18 Million INR | 14.93% |
2013 Q4 | -507.21 Million INR | -205.41% |
2012 Q4 | 387.1 Million INR | 184.01% |
2012 Q1 | 127.8 Million INR | 0.0% |
2012 Q3 | 136.3 Million INR | 4.77% |
2012 Q2 | 130.1 Million INR | 1.8% |
2012 FY | 781.5 Million INR | 16.89% |
2011 FY | 668.54 Million INR | 55.66% |
2010 FY | 429.5 Million INR | 10.74% |
2009 FY | 387.83 Million INR | 23.69% |
2008 FY | 313.56 Million INR | 20.22% |
2007 FY | 260.81 Million INR | -1.77% |
2006 FY | 265.51 Million INR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Sigachi Industries Limited | 579.88 Million INR | -101.329% |
Ind-Swift Limited | 946.56 Million INR | -23.338% |
Bajaj HealthCare Limited | 985.34 Million INR | -18.484% |
Sakar Healthcare Limited | 204.07 Million INR | -472.072% |
Aurobindo Pharma Limited | 55.65 Billion INR | 97.902% |
Innova Captab Limited | 931.03 Million INR | -25.396% |
Divi's Laboratories Limited | 14.17 Billion INR | 91.761% |
AstraZeneca Pharma India Limited | 2.47 Billion INR | 52.801% |
Morepen Laboratories Limited | 1.98 Billion INR | 41.257% |
Mankind Pharma Limited | 29.27 Billion INR | 96.012% |
Sequent Scientific Limited | 2.9 Billion INR | 59.767% |
Wanbury Limited | 978.96 Million INR | -19.256% |
Laurus Labs Limited | 11.9 Billion INR | 90.197% |
Nectar Lifesciences Limited | 932.7 Million INR | -25.172% |
Glenmark Life Sciences Limited | 11.64 Billion INR | 89.971% |
Alembic Limited | 872.45 Million INR | -33.815% |
Hikal Limited | 4.46 Billion INR | 73.846% |
Alembic Pharmaceuticals Limited | 15.86 Billion INR | 92.643% |
Neuland Laboratories Limited | 2.92 Billion INR | 60.151% |
J. B. Chemicals & Pharmaceuticals Limited | 14.79 Billion INR | 92.108% |
Glenmark Pharmaceuticals Limited | 46.95 Billion INR | 97.513% |
IOL Chemicals and Pharmaceuticals Limited | 2.2 Billion INR | 46.957% |
Themis Medicare Limited | 1.12 Billion INR | -3.702% |
RPG Life Sciences Limited | 1.63 Billion INR | 28.616% |
Zydus Lifesciences Limited | 125.21 Billion INR | 99.068% |
Lupin Limited | 125.09 Billion INR | 99.067% |
Amrutanjan Health Care Limited | 2.09 Billion INR | 44.247% |
Wockhardt Limited | 8.48 Billion INR | 86.233% |
Vaishali Pharma Limited | 84.02 Million INR | -1289.376% |
Aarti Pharmalabs Limited | 3.07 Billion INR | 62.026% |
Jagsonpal Pharmaceuticals Limited | 438.55 Million INR | -166.213% |
Jubilant Pharmova Limited | 14.45 Billion INR | 91.923% |
FDC Limited | 3.49 Billion INR | 66.641% |
Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 98.782% |
Kilitch Drugs (India) Limited | 412.42 Million INR | -183.075% |
Eris Lifesciences Limited | 4.94 Billion INR | 76.381% |
Venus Remedies Limited | 1.91 Billion INR | 39.076% |
ZIM Laboratories Limited | 1.01 Billion INR | -15.243% |
Bliss GVS Pharma Limited | 1.41 Billion INR | 17.738% |
Par Drugs and Chemicals Limited | 58.28 Million INR | -1902.948% |
Caplin Point Laboratories Limited | 2.17 Billion INR | 46.31% |
Shilpa Medicare Limited | 3.33 Billion INR | 64.984% |
Albert David Limited | 1.02 Billion INR | -13.773% |
Ajanta Pharma Limited | 30.46 Billion INR | 96.168% |
Hester Biosciences Limited | 908.84 Million INR | -28.458% |
Suven Pharmaceuticals Limited | 1.4 Billion INR | 16.774% |
Solara Active Pharma Sciences Limited | 2.55 Billion INR | 54.29% |
Gufic Biosciences Limited | 1.18 Billion INR | 1.61% |
Windlas Biotech Limited | 1 Billion INR | -15.993% |
Procter & Gamble Health Limited | 2.99 Billion INR | 61.024% |
Aarey Drugs & Pharmaceuticals Limited | 14.21 Million INR | -8114.163% |
Mangalam Drugs & Organics Limited | 162.22 Million INR | -619.653% |
Granules India Limited | 10.31 Billion INR | 88.679% |
Bal Pharma Limited | 555.62 Million INR | -110.12% |
Alkem Laboratories Limited | 32.83 Billion INR | 96.444% |
Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 99.243% |
Lincoln Pharmaceuticals Limited | 1.07 Billion INR | -8.685% |
Medicamen Biotech Limited | 335.16 Million INR | -248.328% |
Unichem Laboratories Limited | 6.72 Billion INR | 82.642% |
Bafna Pharmaceuticals Limited | 455.58 Million INR | -156.259% |
Biofil Chemicals and Pharmaceuticals Limited | 6.82 Million INR | -17018.46% |
Valiant Laboratories Limited | 138.02 Million INR | -745.822% |
Orchid Pharma Limited | 800.77 Million INR | -45.794% |
Medico Remedies Limited | 59.67 Million INR | -1856.395% |
Ind-Swift Laboratories Limited | 2.12 Billion INR | 45.039% |
Ipca Laboratories Limited | 18.98 Billion INR | 93.851% |
Brooks Laboratories Limited | 51.18 Million INR | -2181.123% |
Syncom Formulations (India) Limited | 345.63 Million INR | -237.78% |
Piramal Enterprises Limited | 63.65 Billion INR | 98.166% |
Torrent Pharmaceuticals Limited | 21.42 Billion INR | 94.55% |
NATCO Pharma Limited | 10.05 Billion INR | 88.393% |
Suven Life Sciences Limited | 109.75 Million INR | -963.762% |
Krebs Biochemicals & Industries Limited | 46.15 Million INR | -2429.42% |
Strides Pharma Science Limited | 9.16 Billion INR | 87.258% |
Indoco Remedies Limited | 12.06 Billion INR | 90.32% |
Alpa Laboratories Limited | 127.38 Million INR | -816.532% |
Lasa Supergenerics Limited | 291.17 Million INR | -300.956% |
Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 62.055% |